Your browser doesn't support javascript.
COVID-19 vaccine development and a potential nanomaterial path forward.
Shin, Matthew D; Shukla, Sourabh; Chung, Young Hun; Beiss, Veronique; Chan, Soo Khim; Ortega-Rivera, Oscar A; Wirth, David M; Chen, Angela; Sack, Markus; Pokorski, Jonathan K; Steinmetz, Nicole F.
  • Shin MD; Department of NanoEngineering, University of California San Diego, La Jolla, CA, USA.
  • Shukla S; Department of NanoEngineering, University of California San Diego, La Jolla, CA, USA.
  • Chung YH; Department of Bioengineering, University of California San Diego, La Jolla, CA, USA.
  • Beiss V; Department of NanoEngineering, University of California San Diego, La Jolla, CA, USA.
  • Chan SK; Department of NanoEngineering, University of California San Diego, La Jolla, CA, USA.
  • Ortega-Rivera OA; Department of NanoEngineering, University of California San Diego, La Jolla, CA, USA.
  • Wirth DM; Department of NanoEngineering, University of California San Diego, La Jolla, CA, USA.
  • Chen A; Department of NanoEngineering, University of California San Diego, La Jolla, CA, USA.
  • Sack M; Pro-SPR GmbH, Alsdorf, Germany.
  • Pokorski JK; Department of NanoEngineering, University of California San Diego, La Jolla, CA, USA.
  • Steinmetz NF; Center for Nano-ImmunoEngineering, University of California San Diego, La Jolla, CA, USA.
Nat Nanotechnol ; 15(8): 646-655, 2020 08.
Article in English | MEDLINE | ID: covidwho-646949
ABSTRACT
The COVID-19 pandemic has infected millions of people with no clear signs of abatement owing to the high prevalence, long incubation period and lack of established treatments or vaccines. Vaccines are the most promising solution to mitigate new viral strains. The genome sequence and protein structure of the 2019-novel coronavirus (nCoV or SARS-CoV-2) were made available in record time, allowing the development of inactivated or attenuated viral vaccines along with subunit vaccines for prophylaxis and treatment. Nanotechnology benefits modern vaccine design since nanomaterials are ideal for antigen delivery, as adjuvants, and as mimics of viral structures. In fact, the first vaccine candidate launched into clinical trials is an mRNA vaccine delivered via lipid nanoparticles. To eradicate pandemics, present and future, a successful vaccine platform must enable rapid discovery, scalable manufacturing and global distribution. Here, we review current approaches to COVID-19 vaccine development and highlight the role of nanotechnology and advanced manufacturing.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Viral Vaccines / Coronavirus Infections / Nanostructures / Pandemics Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Nat Nanotechnol Year: 2020 Document Type: Article Affiliation country: S41565-020-0737-y

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Viral Vaccines / Coronavirus Infections / Nanostructures / Pandemics Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Nat Nanotechnol Year: 2020 Document Type: Article Affiliation country: S41565-020-0737-y